Healthcare
Why Amarin (AMRN) Stock May Be a Good Buy Right Now
Amarin (AMRN) has had a lot of attention over its fish oil pill Vascepa, which aims to help those with cardiovascular problems and …
Is Green Growth’s Hostile Bid for Aphria (APHA) All a Show Created to Boost Stock Price?
Aphria (APHA) stock tests investor nerves in roller coaster ride following an announcement Thursday from U.S.
Tilray (TLRY) Stock: Now That’s a Go Ahead!
Canadian pharmaceutical company Tilray (TLRY) announced this week a partnership with beer and beverage giant Anheuser-Busch InBev to research cannabis beverages. The two companies will be investing …
Is Tilray’s (TLRY) New Deal with Novartis So Great?
Medical cannabis maker Tilray (TLRY) announced early Tuesday that it has entered into a global supply and distribution agreement for medical marijuana with …
This Bear Says New Age Beverages Corporation (NBEV) Stock is Doomed; Here’s Why
It’s a new age, alright. Cannabis is becoming more normalized and companies are already capitalizing.
Synergy Pharmaceuticals (SGYP) Stock Crash Holds an Important Lesson, Says Biotech Spectator
As Bausch Health (BHC) attempts to swallow up bankrupt Synergy Pharmaceuticals (SGYP), Seeking Alpha blogger Biotech Spectator (BS) says Synergy’s beloved Irritable Bowel …
Here’s Why Aphria (APHA) Stock Can Easily Rise 40% by the End of the Year
In a dramatic change, Trump announced on Friday that marijuana reform ally Mick Mulvaney will replace marijuana opponent John Kelly as his acting …
Does Amarin’s (AMRN) Impending FDA Decision Matter?
Blogger Christiana Friedman says the FDA decision for Amarin’s (AMRN) drug Vascepa might not be the make or break for the company. In …
Biotech Stocks Will Likely Be the Surprise Big Winner Once Again
By Steve Sjuggerud The last truly great “Melt Up” in U.S.
Here Are My Top 3 Biotech Stocks
By Genia Turanova There’s nothing like cash to show how successful a company has been. When a fledgling enterprise first turns cash-flow positive …
